摘要
目的 观察多西他赛治疗口腔癌术后患者的临床疗效和安全性。方法 将接受顺铂化疗且接受2年随访的口腔癌术后患者资料作为对照组;另将医院同期接受多西他赛联合顺铂化疗且接受2年随访的口腔癌术后患者资料,作为试验组。对照组术后1个月时给予顺铂化疗,于第1~3天给予顺铂75 mg·m^(-2),静脉滴注时间>1 h, 21 d为1个周期,均化疗2个周期;试验组给予多西他赛联合顺铂化疗,顺铂的用药方法同对照组,并于第1天给予多西他赛75 mg·m^(-2),静脉滴注时间>1 h, 21 d为1个周期,均化疗2个周期。比较2组患者的临床疗效、生活质量、生存状况、细胞因子[白细胞介素-2(IL-2)、白细胞介素-4(IL-4)]以及药物不良反应发生情况。结果 对照组40例,试验组50例。治疗后,试验组和对照组的总有效率分别为82.00%(41例/50例)和62.50%(25例/40例),差异有统计学意义(P<0.05)。治疗2个周期后,试验组和对照组的生活质量评分分别为(63.52±3.65)和(51.23±3.42)分;IL-2分别为(246.56±20.58)和(196.58±19.25)pg·mL^(-1);IL-4分别为(369.89±15.21)和(390.21±14.11)pg·mL^(-1),差异均有统计学意义(均P<0.05)。2组随访2年期间,试验组病死4例(8.00%),远处转移5例(10.00%),局部复发11例(22.00%);对照组病死12例(30.00%),远处14例(35.00%),局部复发19例(47.50%),差异均有统计学意义(均P<0.05)。2组药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论 多西他赛联合顺铂比单一使用顺铂治疗口腔癌的疗效更佳,患者生存质量高,生存时间长,且不会增加药物不良反应发生率。
Objective To observe the clinical efficacy and safety of docetaxel in the treatment of postoperative patients with oral cancer.Methods The data of patients with oral cancer who received cisplatin chemotherapy and received 2-year follow-up were taken as the control group.In addition,the data of patients with oral cancer who received docetaxel combined with cisplatin chemotherapy and received 2-year follow-up in the hospital at the same time were used as treatment group.The control group was given cisplatin chemotherapy one month after operation,and cisplatin chemotherapy at dl-d3,75 mg·m^(-2)intravenous drip time>1 h,21 days as a cycle,both chemotherapy for 2 cycles.Treatment group was given docetaxel combined with cisplatin,and cisplatin was used in the same way as the control group,and docetaxel was given on dl,75 mg·m2,and the intravenous drip time was>1 h,and 21 d was a cycle,and both chemotherapy cycles were performed.The clinical efficacy,quality of life,living conditions,cytokines[interleukin-2(IL-2),interleukin-4(IL-4)Jand adverse drug reactions of the two groups were compared.Results There were 40 cases in control group and 50 cases in treatment group.After treatment,the total effective rates of treatment and control groups were 82.00%(41 cases/50 cases)and 62.50%(25 cases/40 cases),the difference was statistically significant(P<0.05).Ater 2 cycles of treatment,the life quality scores of treatment group and control group were(63.52±3.65)and(51.23±3.42)points;IL-2 were(246.56±20.58)and(196.58±19.25)pg·mL^(-1);IL-4were(369.89±15.21)and(390.21±14.11)pg·mL^(-1),and the differences were statistically significant(all P<0.05).During 2-year fllow-up,4 patients died(8.00%),5 patients had distant metastasis(10.00%),and 11 patients had local recurrence(22.00%)in treatment group;and in control group,12 patients died(30.00%),14 patients had distant metastasis(35.00%),and 19 patients suffered local recurrence(47.50%),the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).Conclusion Docetaxel combined with cisplatin is more effective than cisplatin alone in the treatment of oral cancer,with high quality of life and long survival time,and will not increase the incidence of adverse drug reactions.
作者
洪虓
周晶
廖圣恺
HONG Xiao;ZHOU Jing;LIAO Sheng-kai(Department of Stomatology,The First Affliated HospitalofBengbu Medical College,Bengbu 233000,Anhui Province,China;Department of Stomatology,902 Hospital of People's Liberation Army Joint Logistic Support Force,Bengbu 233000,Anhui Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2023年第17期2455-2458,共4页
The Chinese Journal of Clinical Pharmacology
关键词
多西他赛
顺铂
口腔癌
生存时间
生活质量
docetaxel
cisplatin
oral cancer
survival time
quality of life